Abbott Labs (ABT) PT Lowered to $125 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street rises on revived AI momentum as earnings season picks up
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts ABT Hot Sheet
Price: $103.24 -1.56%
Rating Summary:
26 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 17
Rating Summary:
26 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 17
Join SI Premium – FREE
Barclays analyst Travis Steed lowered the price target on Abbott Labs (NYSE: ABT) to $125.00 (from $150.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Argus Downgrades Abbott Labs (ABT) to Hold
- Abbott Labs (ABT) PT Raised to $120 at Bernstein SocGen Group
- JPMorgan Assumes Airtac International (1590:TT) at Overweight
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
